Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6610918 | 0.80 | MAPT (0.52) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL5795700 | 0.79 | MAPT (0.56) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL6613477 | 0.77 | MAPK1 (0.47) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL20837398 | 0.74 | LMNA (0.49) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL74991 | 0.74 | MAPT (0.43) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL7253960 | 0.73 | PDE4B (0.52) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL20837137 | 0.73 | NNMT (0.40) | ALDH1A1KDM4EKMT2AHPGDGAA | |
| SCHEMBL5798828 | 0.72 | MAPT (0.56) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL75121 | 0.72 | MAPT (0.45) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL6168793 | 0.72 | PDE4B (0.46) | MAPTALDH1A1KDM4EKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944616-B1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-07-18 | — | — | US | disclosed |
| US-6353010-B1 | ENZYME INHIBITORS TUMOR NECROSIS FACTOR AND PHOSPHODIESTERASE FOR ANTIINFLAMMATORY AGENTS | DARWIN DISCOVERY, LTD. (GB) | 2002-03-05 | — | — | US | disclosed |
| EP-0944616-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998022460-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | PDE3B, PDE3A, PDE2A | MAPT 4233/4885ALDH1A1 202/4885KDM4E 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.